Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2011-04-12
2011-04-12
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C536S017900
Reexamination Certificate
active
07923013
ABSTRACT:
This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
REFERENCES:
patent: 5405772 (1995-04-01), Ponting
patent: 5663151 (1997-09-01), Martel et al.
patent: 5767092 (1998-06-01), Koezuka et al.
patent: 5936076 (1999-08-01), Higa et al.
patent: 6417167 (2002-07-01), Maruyama et al.
patent: 2007/0238871 (2007-10-01), Tsuji et al.
patent: 1619199 (2006-01-01), None
patent: WO 9320185 (1993-10-01), None
patent: WO 9500632 (1995-01-01), None
patent: WO9506112 (1995-03-01), None
patent: WO2006/026389 (2006-03-01), None
patent: WO2006/071848 (2006-07-01), None
patent: WO2007/035717 (2007-03-01), None
Fujio, M. et al. “Structure-Based Discovery of Glycolipids for CD1d-Mediated NKT Cell Activation: Tuning the Adjuvant versus Immunosuppression Activity,”J. American Chemical Society, 2006, 128(28), p. 9022-9023.
Toba et al. “Minimum structure requirement of immunomodulatory glycolipids for predominant Th2 cytokine induction and the discovery of non-linear phytosphingosine analogs,”Biorganic&Medicinal Chemistry Letters, Oxford, GB, vol. 17, No. 10, 2007, p. 2781-2784.
International Search Report and Written Opinion from PCT/US2008/060061 mailed on Sep. 8, 2008.
Porcelli, S. A. & Modlin, R. L. Annu, “The CD1 System: Antigen-Presenting Molecules for T cell Recognition of Lipids and Glycolipids”, 1999, Annu. Rev. Immunol. 17, pp. 297-329.
Green and P.G.M. Wits, “Protection for the Amino Group,” Protective Groups in Organic Synthesis, 1999, 3rd Edition, pp. 494-653.
Caux et al., GM-CSF and TNF-a Cooperate in the Generation of Dendritic Langerhans Cells, 1992, Nature 360, Palgrave Macmilland Ltd, pp. 258-261.
Romani et al, “Proliferating Dendritic Cell Progenitors in Human Blood,” Journal of Experimental Medicine, 1994, vol. 180, Rockefeller University Press, pp. 83-93.
Bender et al., “Improved Methods for the Generation of Dendritic Cells From Nonproliferating Progenitors in Human Blood,” Journal of Immunological Methods, 1996, vol. 196, Issue 2, Elsevier Science B.V., pp. 121-135.
O'Doherty et al., “Human Blood Contains Two Subsets of Dendritic Cells, One Immunologically Mature and the Other Immature,” Immunology, Jul. 1994, vol. 82, No. 3, pp. 487-493.
O'Doherty et al., “Dendritic Cells Freshly Isolated From Human Blood Express CD4 and Mature Into Typical Immunostimulatory Dendritic Cells After Culture in Monocyte-Conditioned Medium,” Journal of Experimental Medicine, 1993, vol. 178, Rockefeller University Press, pp. 1067-1076.
Xing, G.W., et al., “Synthesis and human NKT cell stimulating properties of 3-0-Sulfo-a/b-galactosylceramides”, Bioorg. Med. Chem, 2005, 15;13(8):2907-2916.
Hsu et al., “Vaccination of Patients with B-Cell Lymphoma Using Autologous Antigen-Pulsed Dendritic Cells,” Nature Medicine 2, 1996, pp. 52-58.
Bonifaz et al., “Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibiilty Complex Class I Products and Peripheral CD8+ T Cell Tolerance,” Dec. 16, 2002, Journal of Experimental Medicine, vol. 196, No. 12, pp. 1627-1638.
Manavalan et al., “High Expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells”, 2003, Transplant Immunology, vol. 11, pp. 245-258.
Kawahara et al., “Occurrence of an a-galacturonosyl-ceramide in the dioxin-degrading bacterium Sphingomonas wittichii,” FEMS Microbiology Letters, Sep. 2002, vol. 214, Issue 2, pp. 289-294.
Kumar et al., “Cutting Edge: CD1d Deficiency Impairs Murine Host Defense Against the Spirochete,Borrelia burgdorferi,” The Journal of Immunology, 2000, vol. 165, pp. 4797-4801.
Ben-Menachem et al., “A Newly Discovered Cholesteryl Galactoside fromBorrelia burgdorferi,” Microbiology, 2003, vol. 100, No. 13, pp. 7913-7918.
Figueroa-Perez, S. et al., “Total synthesis of a-galactosyl cerebroside”, Carbohydrate Research, 2000, vol. 328, 95-102.
Plettenburg, O. et al., “Synthesis of a-Galactosyl Ceramide, a Potent Immunostimulatory Agent”, J. Org. Chem., 2002, 67, 4559-4564.
Compostella, F. et al. “CD1a-binding glycosphingolipids stimulating human autoreactive T-cells; synthesis of a family of sulfatides differing in the acyl chain moiety”, Tetrahedron 2002, 58, 8703-8708.
Williams, L. et al. “Grignard Reactions to Chiral Oxazolidine Aldehydes”, Tetrahedron, 1996, 52:11673-11694.
Sidobre et al., “The T Cell Antigen Receptor Expressed by Va14i NKT Cells has a Unique Mode of Glycosphingolipid Antigen Recognition,” PNAS, Aug. 17, 2004, vol. 101, No. 33, pp. 12254-12259.
Zeng et al., “Crystal Structure of Mouse CD1: An MHC-Like Fold with a Large Hydrophobic Binding Groove”, Science, 1997, vol. 277, pp. 339-345.
Morris, G.M. et al., “Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energey Function,” Journal of Computational Chemistry, John Wiley & Sons, Inc., 1998, vol. 19, Issue 14, pp. 1639-1662.
Goff, R.D., et al., “Effects of Lipid Chain Lengths in a-Galactosylceramides on Cytokine Release by Natural Killer T Cells”, Journal Am. Chem. Soc., 2004, vol. 126, pp. 13602-13603.
Shirota et al., “Phytosphingosines—A Facile Synthesis and Spectroscopic Protocol for Configurational Assingment”, Tetrahedron, 1999, vol. 55, pp. 13643-13658.
Elewaut D., et al., The Adaptor Protein AP-3 is Require for CD1d-Mediated Antigen Presentation of Glycosphingolipids and Development of Va14i NKT Cells, Journal of Experimental Medicine, 2003, vol. 198, pp. 1133-1146.
Wu, D. et al., “Bacterial Glycolipids and Analogs as Antigens for CD1d-Restricted NKT Cells,” PNAS, 2005, vol. 102, No. 5, pp. 1351-1356.
Deng, S.Y., et al., “Highly Efficient Glycosylation of Sapogenins”, J. Org. Chem. 1999, 64:7265-7266.
Koch, M., et al., “The crystal structure of human CD1d with and without a-galactosylceramide”, Nat. Immunol., 2005 6:819-826.
International Search Report and Written Opinion from PCT/US05/47017 mailed Jul. 25, 2006.
Zajonc, D. et al. “Structure and Function of a Potent Agonist for the Semi-Invariant NKT Cell Receptor”, Nat. Immunol., 2005 6(8): 810-818.
Kinjo, Y. et al. “Recognition of bacterial glycosphingolipids by natural killer T cells”, Nature, 2005, vol. 434, pp. 520-525.
Fujio, M. et al. “Structure-Based Discovery of Glycolipids for Cd1d-Mediated NKT Cell Activation: Tuning the Adjuvant versus Immunosuppression Activity”. J. Am. Chem. Soc., 2006, 128, 9022-9023.
Fujio Masakazu
Ho David D.
Li Xiangming
Tsuji Moriya
Wong Chi-Huey
Gonsalves Andrew K.
Heslin Rothenberg Farley & & Mesiti P.C.
Peselev Elli
The Rockefeller University
The Scripps Research Institute
LandOfFree
Glycolipids and analogues thereof as antigens for NKT cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycolipids and analogues thereof as antigens for NKT cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycolipids and analogues thereof as antigens for NKT cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2710154